Table 1.
Characteristics of participants
| Characteristics of participants | |
|---|---|
| Number | 7 |
| Gender (male/female) | 6/1 |
| Age median (range) | 47 (35–59) |
| Radiographic stage (0/I/II/III/IV) | (0/0/3/0/4) |
| VC % predicted, median (range) | 98 (72–124) |
| FEV1 % predicted, median (range) | 79 (62–136) |
| Dyspnoea score (1–7) at baseline, median (range) | 5·4 (4·2–7) |
| Fatigue score (1–7) at baseline, median (range) | 4 (1–6·2) |
| Immunosupressive treatment (Predn/Predn+MTX/MTX) | 5/1/1 |
Predn = prednisolone, MTX = methotrexate. Prednisolone dose ranged from 5 to 15 mg daily. Methotrexate dose ranged from 10 to 15 mg/week. VC = vital capacity; FEV1 = forced expiratory volume in 1 s.